Congress funds antibiotic-resistance research network to combat drug-resistant infections
S. 5237 — Stop Superbugs Act · Filed by Maggie Hassan (D-NH) · 1 cosponsor · Introduced Aug 4, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill directs the National Institute of Allergy and Infectious Diseases (NIAID) to award a competitive grant to the Antibiotic Resistance Leadership Group to establish a clinical research network focused on antibiotic resistance. The network will support faster recruitment of trial participants, community outreach, pairing of diagnostic and drug innovations in trials, and development of patient-reported outcome measures. Congress authorizes whatever funding is needed.
Why we flagged it
The bill is a straightforward appropriations authorization for clinical research infrastructure addressing antibiotic resistance, a documented public-health priority. It contains no tax provisions, regulatory changes, or private carve-outs.
What the text implies
- The bill does not specify funding amount, leaving appropriations to future congressional action—actual research capacity depends on whether Congress later votes to fund it.
- The 'Antibiotic Resistance Leadership Group' is not defined in the bill text; its structure, governance, and composition are left to NIAID discretion, creating implementation flexibility but also potential for mission drift.
The full analysis lists 3 implications of this text.
Who stands to gain
research institutions and universities (as grant recipients); clinical trial networks and research coordinators; diagnostic and pharmaceutical companies (through pairing innovations in trials)